2. Academic Validation
  3. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

  • Oncoimmunology. 2018 Aug 1;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356.
Mohamed H S Awwad 1,  Katharina Kriegsmann 1,  Julian Plaumann 1,  Michael Benn 1,  Jens Hillengass 1,  Marc S Raab 1,  Uta Bertsch 1 2,  Markus Munder 3,  Katja Weisel 4,  Hans Jürgen Salwender 5,  Mathias Hänel 6,  Roland Fenk 7,  Jan Dürig 8,  Carsten Müller-Tidow 1,  Hartmut Goldschmidt 1 2,  Michael Hundemer 1
Affiliations

Affiliations

  • 1 Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
  • 2 National Center for Tumour Diseases, University of Heidelberg, Heidelberg, Germany.
  • 3 Department of Hematology, Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • 4 Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.
  • 5 Asklepios Klinik Hamburg Altona, Germany.
  • 6 Klinikum Chemnitz, Germany.
  • 7 Department of Hematology, Oncology and Clinical Immunology, University Düsseldorf, Düsseldorf, Germany.
  • 8 Department of Hematology, University of Essen, Essen, Germany.
PMID: 30288348 DOI: 10.1080/2162402X.2018.1486356
Abstract

Purpose: While recent studies described the role of IKZF1/3 proteins in multiple myeloma (MM) cells, few have highlighted the significance of IKZF1/3 expression in T-cells. In this study we examine the prognostic and predictive value of IKZF1/3 expression in T-cells in patients with MM stage III. Experimental design: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value. We also combined in vivo observations with in vitro assays to determine the effect of IKZF1/3 expression on the T-cell immunophenotype and anti-tumour T-cell response in 162 MMIII patients. Results: We found that high IKZF3, but not IKZF1, expression in T-cells correlates with superior overall survival in MMIII patients treated with immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide). Moreover, we show that higher IKZF3 expression in T-cells inhibits myeloma-specific T-cell response in vitro and that the immunophenotype of patients with high IKZF3 expression shows features that are contrary to the changes induced by immunomodulatory drugs. Although we observed higher IKZF3 expression levels in T-cells from patients with MMIII compared to MMI, IKZF3 expression was unaffected by the tumour microenvironment. Conclusion: In conclusion, IKZF3 expression in T-cells is a predictive value for clinical outcome in MMIII patients treated with immunomodulatory drugs due to its profound modulation of T-cell functionality.

Keywords

IKZF1; IKZF3; Multiple myeloma; T cells; biomarker trials; immune; immunomodulatory drugs.

Figures